H. Lundbeck AS (LTS:0ND5) Stock Price, Trades & News

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.18
Equity-to-Asset	0.49
Debt-to-Equity	0.43
Debt-to-EBITDA	2
Interest Coverage	9.87
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.52	Distress Grey Safe
Beneish M-Score	-2.48	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

3/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	10.5
	3-Year EBITDA Growth Rate	16.1
	3-Year EPS without NRI Growth Rate	16.3
	3-Year FCF Growth Rate	21.7
	3-Year Book Growth Rate	6.2
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	7.91
	Future 3-5Y Total Revenue Growth Rate Estimate	2.31

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	36.34
	9-Day RSI	41.75
	14-Day RSI	44.6
	3-1 Month Momentum %	-0.35
	6-1 Month Momentum %	0.96
	12-1 Month Momentum %	22.81

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.41
	Quick Ratio	0.9
	Cash Ratio	0.22
	Days Inventory	342.82
	Days Sales Outstanding	74.76
	Days Payable	357.07

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.74
	Dividend Payout Ratio	0.31
	Forward Dividend Yield %	2.74
	5-Year Yield-on-Cost %	2.74
	Shareholder Yield %	-2

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	82.44
	Operating Margin %	22.46
	Net Margin %	14.49
	EBITDA Margin %	21.39
	FCF Margin %	18.91
	OCF Margin %	21.35
	ROE %	14.86
	ROA %	7.02
	ROIC %	9.63
	3-Year ROIIC %	11.24
	ROC (Joel Greenblatt) %	125.38
	ROCE %	12.32
	Years of Profitability over Past 10-Year	10
	Moat Score	7
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	9.62
	Forward PE Ratio	11.08
	PE Ratio without NRI	9.62
	Shiller PE Ratio	4.1
	Price-to-Owner-Earnings	13.99
	PS Ratio	1.39
	PB Ratio	1.39
	Price-to-Free-Cash-Flow	7.4
	Price-to-Operating-Cash-Flow	6.55
	EV-to-EBIT	8.99
	EV-to-Forward-EBIT	9.63
	EV-to-EBITDA	8.99
	EV-to-Forward-EBITDA	7.18
	EV-to-Revenue	1.91
	EV-to-Forward-Revenue	1.9
	EV-to-FCF	10.27
	Price-to-GF-Value	0.89
	Price-to-Projected-FCF	0.71
	Earnings Yield (Greenblatt) %	11.12
	FCF Yield %	12.04
	Forward Rate of Return (Yacktman) %	4.43

Financials (Next Earnings Date:2026-08-19)

Annual Quarterly TTM

LTS:0ND5's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

H. Lundbeck AS Operating Data

Annual Quarterly

LTS:0ND5's Complete Operating Data

No operating data available for H. Lundbeck AS.

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

H. Lundbeck AS Executives

Details

GF Value™: kr46.92

LTS:0ND5

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 0ND5. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil kr)	25,520
	EPS (TTM) (kr)	3.73
	Beta	0.2253
	3-Year Sharpe Ratio	0.31
	3-Year Sortino Ratio	0.49
	Volatility %	26.02
	14-Day RSI	44.6
	14-Day ATR (kr)	0.829201
	20-Day SMA (kr)	42.377698
	12-1 Month Momentum %	22.81
	52-Week Range (kr)	33.34 - 47.44
	Shares Outstanding (Mil)	992.4

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

H. Lundbeck AS Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

H. Lundbeck AS Stock Events

Financials Calendars

Event	Date	Price (kr)
Third quarter earnings conference call for 2026	2026-11-11	In 102 days
Third quarter earnings results for 2026	2026-11-11	In 102 days
Second quarter earnings conference call for 2026	2026-08-19	In 18 days
Second quarter earnings results for 2026	2026-08-19	In 18 days
First quarter earnings conference call for 2026	2026-05-13 13:00	44.88 (+5.85%)
First quarter earnings results for 2026	2026-05-13	44.88 (+5.85%)
DKK 1.150000 Cash Dividend	2026-03-19	37.88 (+0.31%)
General meeting for 2026	2026-03-18 10:00	37.53 (-0.45%)
Fourth quarter earnings conference call for 2025	2026-02-04 11:00	42.90 (-0.32%)
Annual report for 2025	2026-02-04	42.90 (-0.32%)

Show

Entries

H. Lundbeck AS Frequently Asked Questions

What is H. Lundbeck AS(LTS:0ND5)'s stock price today?

The current price of LTS:0ND5 is kr41.99. The 52 week high of LTS:0ND5 is kr47.44 and 52 week low is kr33.34.

When is next earnings date of H. Lundbeck AS(LTS:0ND5)?

The next earnings date of H. Lundbeck AS(LTS:0ND5) is 2026-08-19.

Does H. Lundbeck AS(LTS:0ND5) pay dividends? If so, how much?

The Dividend Yield % of H. Lundbeck AS(LTS:0ND5) is 2.74% (As of Today), Highest Dividend Payout Ratio of H. Lundbeck AS(LTS:0ND5) was 0.31. The lowest was 0.25. And the median was 0.25. The Forward Dividend Yield % of H. Lundbeck AS(LTS:0ND5) is 2.74%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy	2026-07-23
	Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)	2026-07-20
	Tarek Samad appointed EVP, Head of Research & Development at Lundbeck	2026-06-24
	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026	2026-06-15
	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026	2026-06-10
	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress	2026-06-04
	Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting	2026-04-13
	Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026	2026-03-16
	Lundbeck appoints Chief AI Officer	2026-03-10
	Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference	2026-01-30

10/Page

Articles on H. Lundbeck AS

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.